Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.

Cochrane Database Syst Rev. 2018 May 9;5:CD009069. doi: 10.1002/14651858.CD009069.pub3. Review.

PMID:
29740819
2.

Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups.

Latsuzbaia A, Arbyn M, Weyers S, Mossong J.

Vaccine. 2018 Apr 25;36(18):2411-2416. doi: 10.1016/j.vaccine.2018.03.054. Epub 2018 Mar 27.

3.

Complete Genome Sequence of a Novel Human Gammapapillomavirus Isolated from a Cervical Swab in Luxembourg.

Latsuzbaia A, Arbyn M, Dutta S, Fischer M, Gheit T, Tapp J, Tommasino M, Weyers S, Mossong J.

Genome Announc. 2018 Mar 15;6(11). pii: e00114-18. doi: 10.1128/genomeA.00114-18.

4.

Assessing factors associated with long-term work disability after cancer in Belgium: a population-based cohort study using competing risks analysis with a 7-year follow-up.

Kiasuwa Mbengi RL, Nicolaie AM, Goetghebeur E, Otter R, Mortelmans K, Missinnne S, Arbyn M, Bouland C, de Brouwer C.

BMJ Open. 2018 Feb 17;8(2):e014094. doi: 10.1136/bmjopen-2016-014094.

5.

Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261. [Epub ahead of print] Review.

PMID:
29341110
6.

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.

Xu L, Oštrbenk A, Poljak M, Arbyn M.

J Clin Virol. 2018 Jan;98:37-42. doi: 10.1016/j.jcv.2017.12.001. Epub 2017 Dec 6.

PMID:
29241150
7.

Overcoming barriers in HPV vaccination and screening programs.

Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjosé S, Hanley S, Karafillakis E, Lopalco PL, Pollock KG, Yarwood J, Van Damme P.

Papillomavirus Res. 2017 Dec;4:45-53. doi: 10.1016/j.pvr.2017.07.001. Epub 2017 Jul 20.

8.

Cervical morbidity in Alsace, France: results from a regional organized cervical cancer screening program.

Baldauf JJ, Fender M, Bergeron C, Marrer E, Velten M, Pradat P, Arbyn M.

Eur J Cancer Prev. 2017 Nov 13. doi: 10.1097/CEJ.0000000000000415. [Epub ahead of print]

PMID:
29135538
9.

Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.

Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, Petry KU, Leeson S, Bergeron C, Nieminen P, Gondry J, Reich O, Moss EL.

Lancet Oncol. 2017 Dec;18(12):1665-1679. doi: 10.1016/S1470-2045(17)30700-3. Epub 2017 Nov 7. Review.

PMID:
29126708
10.

Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.

Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, Arbyn M, Bennett P, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Nov 2;11:CD012847. doi: 10.1002/14651858.CD012847. Review.

PMID:
29095502
11.

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.

Polman NJ, Oštrbenk A, Xu L, Snijders PJF, Meijer CJLM, Poljak M, Heideman DAM, Arbyn M.

J Clin Microbiol. 2017 Dec;55(12):3544-3551. doi: 10.1128/JCM.01282-17. Epub 2017 Oct 11.

12.

Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.

Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, Wilson A, Patterson L, Govan L, Black J, Palmer T, Arbyn M.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1629-1635. doi: 10.1158/1055-9965.EPI-17-0534. Epub 2017 Sep 8.

PMID:
28887297
13.

Pregnancy outcome after cervical conisation: A 2nd retrospective cohort study in the Leuven University Hospital.

van Velthoven K, Poppe W, Verschuere H, Arbyn M.

Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:224-231. doi: 10.1016/j.ejogrb.2017.06.043. Epub 2017 Jun 29.

PMID:
28822944
14.

Cytology versus HPV testing for cervical cancer screening in the general population.

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M.

Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587. doi: 10.1002/14651858.CD008587.pub2. Review.

PMID:
28796882
15.

Impact of anaesthesia mode on evaluation of LEEP specimen dimensions.

Mercuzot A, Chevreau J, Sevestre H, Muszynski C, Arbyn M, Sergent F, Gondry J.

J Gynecol Obstet Hum Reprod. 2017 Apr;46(4):339-342. doi: 10.1016/j.jogoh.2016.12.006. Epub 2017 Jan 30.

PMID:
28643661
16.

Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis.

Catarino R, Schäfer S, Vassilakos P, Petignat P, Arbyn M.

BJOG. 2018 Apr;125(5):545-553. doi: 10.1111/1471-0528.14783. Epub 2017 Jul 26. Review.

PMID:
28603909
17.

Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India.

Gheit T, Anantharaman D, Holzinger D, Alemany L, Tous S, Lucas E, Prabhu PR, Pawlita M, Ridder R, Rehm S, Bogers J, Maffini F, Chiocca S, Lloveras B, Kumar RV, Somanathan T, de Sanjosé S, Castellsagué X, Arbyn M, Brennan P, Sankaranarayanan R, Pillai MR, Gangane N, Tommasino M; HPV-AHEAD study group.

Int J Cancer. 2017 Jul 1;141(1):143-151. doi: 10.1002/ijc.30712. Epub 2017 Apr 19.

PMID:
28369859
18.

HPV-based cervical cancer screening- facts, fiction, and misperceptions.

Wentzensen N, Arbyn M.

Prev Med. 2017 May;98:33-35. doi: 10.1016/j.ypmed.2016.12.040. Epub 2017 Feb 6.

19.

Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.

Latsuzbaia A, Hebette G, Fischer M, Arbyn M, Weyers S, Vielh P, Schmitt F, Mossong J.

Diagn Cytopathol. 2017 May;45(5):384-390. doi: 10.1002/dc.23678. Epub 2017 Mar 1.

PMID:
28247516
20.

Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.

Kyrgiou M, Kalliala IE, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, Cruickshank M, Arbyn M, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Jan 26;1:CD009836. doi: 10.1002/14651858.CD009836.pub2. Review.

21.

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S.

Int J Cancer. 2017 May 15;140(10):2192-2200. doi: 10.1002/ijc.30579. Epub 2017 Jan 11. Review.

22.

Harms of cervical cancer screening in the United States and the Netherlands.

Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, M C M de Kok I, van Kemenade F, Field TS, van Rosmalen J, Brown ML.

Int J Cancer. 2017 Mar 1;140(5):1215-1222. doi: 10.1002/ijc.30524.

23.

Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.

Prigge ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M.

Int J Cancer. 2017 Mar 1;140(5):1186-1198. doi: 10.1002/ijc.30516. Epub 2016 Dec 2. Review.

24.

Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination.

Arbyn M, Vanden Broeck D, Bogers J, Van Damme P, Temmerman M, Weyers S.

Cancer Epidemiol. 2016 Dec;45:178-179. doi: 10.1016/j.canep.2016.10.017. Epub 2016 Nov 12. No abstract available.

PMID:
27847177
25.

Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.

Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC, Khan MJ.

Ann Intern Med. 2017 Jan 17;166(2):118-127. doi: 10.7326/M15-2735. Epub 2016 Nov 15. Review.

PMID:
27842420
26.

ANOVA model for network meta-analysis of diagnostic test accuracy data.

Nyaga VN, Aerts M, Arbyn M.

Stat Methods Med Res. 2018 Jun;27(6):1766-1784. doi: 10.1177/0962280216669182. Epub 2016 Sep 20.

PMID:
27655805
27.

Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.

Kyrgiou M, Kalliala I, Mitra A, Ng KY, Raglan O, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Arbyn M.

Int J Cancer. 2017 Jan 1;140(1):216-223. doi: 10.1002/ijc.30419. Epub 2016 Oct 12. Review.

28.

Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis.

Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E.

BMJ. 2016 Jul 28;354:i3633. doi: 10.1136/bmj.i3633. Review.

29.

Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections.

Jentschke M, Chen K, Arbyn M, Hertel B, Noskowicz M, Soergel P, Hillemanns P.

J Clin Virol. 2016 Sep;82:46-50. doi: 10.1016/j.jcv.2016.06.016. Epub 2016 Jun 28.

PMID:
27434147
30.

Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M.

J Clin Microbiol. 2016 Sep;54(9):2337-42. doi: 10.1128/JCM.00897-16. Epub 2016 Jul 6.

31.

Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MNC, van Doorn LJ, Snijders PJF, Meijer CJLM, Quint WGV, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.

32.

Reply to HPV test results provide useful risk stratification information in women with ASC-H Pap test findings.

Arbyn M, Xu L, Wentzensen N.

Cancer Cytopathol. 2016 Oct;124(10):754-755. doi: 10.1002/cncy.21754. Epub 2016 Jun 23. No abstract available.

33.

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.

Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M.

J Clin Virol. 2016 Aug;81:6-11. doi: 10.1016/j.jcv.2016.05.004. Epub 2016 May 19.

PMID:
27262102
34.

Analytical performance evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples.

Latsuzbaia A, Tapp J, Nguyen T, Fischer M, Arbyn M, Weyers S, Mossong J.

Diagn Microbiol Infect Dis. 2016 Jul;85(3):318-322. doi: 10.1016/j.diagmicrobio.2016.04.011. Epub 2016 Apr 19.

PMID:
27156793
35.

Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, Arbyn M.

BMJ Open. 2016 Apr 25;6(4):e010660. doi: 10.1136/bmjopen-2015-010660.

36.

Barriers and opportunities for return-to-work of cancer survivors: time for action--rapid review and expert consultation.

Kiasuwa Mbengi R, Otter R, Mortelmans K, Arbyn M, Van Oyen H, Bouland C, de Brouwer C.

Syst Rev. 2016 Feb 24;5:35. doi: 10.1186/s13643-016-0210-z. Review.

37.

Surveillance of effects of HPV vaccination in Belgium.

Arbyn M, Broeck DV, Benoy I, Bogers J, Depuydt C, Praet M, Sutter PD, Hoorens A, Hauben E, Poppe W, Van Ranst M, Delvenne P, Gofflot S, Pétein M, Engelen F, Vanneste A, Beeck LO, Damme PV, Temmerman M, Weyers S.

Cancer Epidemiol. 2016 Apr;41:152-8. doi: 10.1016/j.canep.2015.12.011. Epub 2016 Feb 16.

PMID:
26895623
38.

World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer.

Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, Franco EL, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group.

Int J Gynaecol Obstet. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038. Epub 2015 Dec 14.

PMID:
26868062
39.

Triage of HPV positive women in cervical cancer screening.

Wentzensen N, Schiffman M, Palmer T, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S49-S55. doi: 10.1016/j.jcv.2015.11.015. Epub 2015 Nov 28. Review.

40.

Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer.

Xu L, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M.

Cancer Cytopathol. 2016 Apr;124(4):261-72. doi: 10.1002/cncy.21661. Epub 2015 Nov 30. Review.

41.

HPV testing in the context of post-treatment follow up (test of cure).

Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M.

J Clin Virol. 2016 Mar;76 Suppl 1:S56-S61. doi: 10.1016/j.jcv.2015.10.008. Epub 2015 Oct 22. Review.

PMID:
26525202
42.

VALGENT: A protocol for clinical validation of human papillomavirus assays.

Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W.

J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21. doi: 10.1016/j.jcv.2015.09.014. Epub 2015 Oct 8. Review.

PMID:
26522865
43.

Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidi M, Athanasiou A, Martin-Hirsch PP, Bennett P, Paraskevaidis E.

Cochrane Database Syst Rev. 2015 Sep 29;(9):CD008478. doi: 10.1002/14651858.CD008478.pub2. Review.

44.

WITHDRAWN: Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections.

Jentschke M, Chen K, Arbyn M, Hertel B, Noskowicz M, Soergel P, Hillemanns P.

J Clin Virol. 2015 Aug 28. pii: S1386-6532(15)00646-0. doi: 10.1016/j.jcv.2015.08.011. [Epub ahead of print]

PMID:
26358862
45.

Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.

Rossi PG, Ronco G, Dillner J, Elfström KM, Snijders PJ, Arbyn M, Berkhof J, Carozzi F, Del Mistro A, De Sanjosè S, Bosch X, Petry KU, Poljak M, Naldoni C, Meijer CJ; Comparing Health Services Interventions for the Prevention of HPV-Related Cancer Consortium; New Technologies for Cervical Cancer Group.

Cancer Cytopathol. 2016 Jan;124(1):66-7. doi: 10.1002/cncy.21622. Epub 2015 Sep 10. No abstract available.

46.

HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJ, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J.

Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. doi: 10.1038/nrclinonc.2015.146. Epub 2015 Sep 1. Review.

PMID:
26323382
47.

Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials.

Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M.

Eur J Cancer. 2015 Nov;51(16):2375-85. doi: 10.1016/j.ejca.2015.07.006. Epub 2015 Aug 18. Review.

PMID:
26296294
48.

Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors.

Feoli F, Renard C, Abouyahia M, De Wind R, Larsimont D, Arbyn M.

Acta Cytol. 2015;59(3):265-72. doi: 10.1159/000430882. Epub 2015 Aug 12.

PMID:
26279075
49.

Correction: Barriers to and Facilitators of Compliance with Clinic-Based Cervical Cancer Screening: Population-Based Cohort Study of Women Aged 23-60 Years.

Östensson E, Alder S, Elfström KM, Sundström K, Zethraeus N, Arbyn M, Andersson S.

PLoS One. 2015 Aug 6;10(8):e0135534. doi: 10.1371/journal.pone.0135534. eCollection 2015. No abstract available.

50.

Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M.

J Clin Microbiol. 2015 Oct;53(10):3272-9. doi: 10.1128/JCM.01366-15. Epub 2015 Aug 5.

Supplemental Content

Support Center